ArticleCancers2023

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.

Filippo De Braud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.